What are the main reasons Amgen provides non-GAAP financial results?

Amgen provides non-GAAP financial results to offer investors a more insightful view of its ongoing operational performance and future prospects. They believe these measures facilitate better comparisons of results across different periods by excluding items that may be volatile or not representative of core business activities, such as acquisition-related expenses, restructuring costs, and certain legal settlements.

What types of expenses are excluded from Amgen's non-GAAP financial measures?

The primary expenses excluded from Amgen's non-GAAP calculations are acquisition-related expenses (like amortization of acquired intangible assets), net charges from restructuring initiatives (such as severance and facility-related costs), and specific legal judgments or settlements that are considered outside the ordinary course of business.

How does Amgen define Free Cash Flow (FCF) and why is it important?

Amgen defines Free Cash Flow (FCF) as operating cash flow minus capital expenditures, both calculated in accordance with GAAP. The company presents FCF as an additional measure of its liquidity, providing investors with insight into the cash generated from its operations after accounting for investments in its business.

Is the information in this 8-K considered 'filed' with the SEC?

For purposes of Section 18 of the Securities Exchange Act of 1934, the information furnished under Item 2.02 of this Current Report, including the press release, is not considered 'filed.' It is provided to inform investors of the company's results but does not carry the same legal implications as formally filed information unless specifically stated otherwise in future filings.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) filed an 8-K on July 30, 2019, to report its unaudited financial results for the three and six months ended June 30, 2019. The report primarily furnished a press release detailing these results. Investors should note that Amgen presented both GAAP and non-GAAP financial measures, with a clear explanation of the adjustments made to arrive at the non-GAAP figures. These adjustments include acquisition-related expenses (primarily amortization of acquired intangible assets), net charges from restructuring initiatives, and certain legal settlements outside the ordinary course of business. The company believes that these non-GAAP measures, along with Free Cash Flow (FCF), offer a more enhanced view of its ongoing business performance and facilitate comparisons across periods. This disclosure is crucial for investors seeking to understand the underlying operational trends and liquidity of Amgen, separate from the impact of significant one-time or irregular items.

Key Highlights

1Amgen announced its unaudited financial results for the Q2 and H1 2019 period via a press release furnished with the 8-K.
2The company provided both GAAP and non-GAAP financial results, with a detailed reconciliation of adjustments for the latter.
3Key non-GAAP adjustments include acquisition-related expenses (intangible asset amortization), restructuring charges, and certain legal settlements.
4Amgen also reported Free Cash Flow (FCF), defined as operating cash flow less capital expenditures, as a measure of liquidity.
5The company utilizes non-GAAP measures to provide a clearer view of ongoing business performance and facilitate period-to-period comparisons.
6The press release itself, containing the detailed financial results, is the primary document of interest for investors.
7The information furnished under Item 2.02 is not considered 'filed' for certain regulatory purposes and is not automatically incorporated into other SEC filings.

AMGEN INC 8-K Report, Financial Results (Jul 30, 2019)

Summary

Key Highlights

Frequently Asked Questions